Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 Volasertib
0.31623
PLK
Cell cycle
 -0.5731 0.35261
HCC1937 Ceritinib
10.0
ALK
RTK
 -0.5730 0.61105
MDA-MB-361 Topotecan
1.0
Topo I
Chemotherapy
 -0.5729 0.37622
MDA-MB-361 Taselisib
0.1
PI3Ka, g, d
PI3K/mTOR
 -0.5723 0.42418
Hs 578T Cediranib
10.0
VEGFR/cKIT
RTK
 -0.5723 0.81093
HCC1500 Dinaciclib
1.0
pan CDK
Cell cycle
 -0.5720 0.47597
PDX1258 Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.5707 0.64769
SUM149PT Dinaciclib
0.1
pan CDK
Cell cycle
 -0.5705 0.83197
MDA-MB-361 Doxorubicin
0.31623
Chemo
Chemotherapy
 -0.5701 0.41048
MDA-MB-157 Taxol
0.1
Chemo
Chemotherapy
 -0.5699 0.55585
PDXHCI002 AZD7762
3.1623
CHK1/2
Cell cycle
 -0.5697 0.64335
MDA-MB-453 Torin2
0.31623
mTOR/ATM/ATR
PI3K/mTOR
 -0.5693 0.53463
SUM149PT Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.5676 0.82399
HCC70 Tivantinib
10.0
MET
RTK
 -0.5657 0.23225
CAMA-1 Tivantinib
3.1623
MET
RTK
 -0.5655 0.65245
HCC1500 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.5647 0.49013
HCC1806 Etoposide
10.0
Topo II
Chemotherapy
 -0.5629 0.58641
MDA-MB-468 Topotecan
10.0
Topo I
Chemotherapy
 -0.5627 0.65476
PDX1258 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.5611 0.58096
SUM149PT Dinaciclib
1.0
pan CDK
Cell cycle
 -0.5605 0.81650
MDA-MB-157 Volasertib
1.0
PLK
Cell cycle
 -0.5602 0.32482
MDA-MB-134-VI Tivantinib
1.0
MET
RTK
 -0.5598 0.40212
HCC1428 Doxorubicin
1.0
Chemo
Chemotherapy
 -0.5596 0.61438
HCC1500 Doxorubicin
1.0
Chemo
Chemotherapy
 -0.5592 0.49339
PDX1328 Vorinostat
10.0
HDAC
Misc
 -0.5588 0.34491